|1.||Berkowitz, R S: 5 articles (07/2000 - 03/2000)|
|2.||Mok, S C: 5 articles (07/2000 - 03/2000)|
|3.||Muto, M G: 5 articles (07/2000 - 03/2000)|
|4.||Welch, W R: 5 articles (07/2000 - 03/2000)|
|5.||Bell, D A: 4 articles (07/2000 - 03/2000)|
|6.||Huang, L W: 3 articles (07/2000 - 03/2000)|
|7.||Garrett, A P: 3 articles (07/2000 - 03/2000)|
|8.||Schorge, J O: 3 articles (07/2000 - 03/2000)|
|9.||Ehrich, M: 2 articles (01/2005 - 12/2001)|
|10.||Morishita, Takashi: 1 article (01/2015)|
03/01/1998 - "The routine histologic and immunocytochemical studies of tumor tissue, obtained during the patient's lifetime and at autopsy, validated the unique occurrence of PSCP in a man. "
07/01/2000 - "The high LOH rate identified on 6q, 9p, 17p, 17q, and Xq in PSCP suggests that candidate tumor suppressor genes residing in these regions may be important for the development of the tumor. "
04/01/2000 - "Finding the mutation in only one of multiple tumor sites in the PSCP case supports growing evidence for a multifocal origin of PSCP. "
04/01/2000 - "In the single PSCP case with a K-ras mutation, the mutation was found in only one of five tumor sites tested. "
03/01/2000 - "In addition, the finding of different patterns of allelic loss at different tumor sites within the same patient indicate a mutifocal origin in some PSCP cases. "
04/14/2006 - "Sub-lethal concentrations of the organophosphate phenyl saligenin phosphate (PSP) inhibited the outgrowth of axon-like processes in differentiating mouse N2a neuroblastoma cells (IC(50) 2.5 microM). "
12/01/2009 - "Effects of phenyl saligenin phosphate on cell viability and transglutaminase activity in N2a neuroblastoma and HepG2 hepatoma cell lines."
01/01/2005 - "Concentration- and time-response studies were done in neuroblastoma cells exposed to phenyl saligenin phosphate (PSP) and mipafox, both compounds that readily induce delayed neuropathy in hens, or paraoxon, which does not. "
04/14/2006 - "Inhibition of neurite outgrowth in differentiating mouse N2a neuroblastoma cells by phenyl saligenin phosphate: effects on MAP kinase (ERK 1/2) activation, neurofilament heavy chain phosphorylation and neuropathy target esterase activity."
12/01/2001 - "We, therefore, investigated changes in f-actin in SH-SY5Y human neuroblastoma cells exposed to 0.1 and 1 mM paraoxon, parathion, phenyl saligenin phosphate (PSP), tri-ortho-tolyl phosphate (TOTP), triphenyl phosphite (TPPi), and di-isopropyl phosphorofluoridate (DFP) for 0-48 h. "
05/01/2009 - "Papillary serous carcinoma of the peritoneum (PSCP) has been recognized for almost 5 decades, but little is known about the etiology or pathogenesis of this uncommon malignancy. "
01/01/2009 - "Since the patient had been treated surgically for primary papillary serous carcinoma of the peritoneum (PSCP) 10 years earlier, immunohistochemical examinations were performed. "
01/01/2007 - "She was finally diagnosed with primary papillary serous carcinoma of the peritoneum (PSCP). "
07/01/2000 - "Compared with allelic loss of serous epithelial ovarian carcinoma (SEOC), the frequency of LOH was significantly lower in PSCP on 1p, 7q, 11p, 17p, and 17q. "
03/01/2000 - "Comparing these results with our cases of advanced staged invasive serous epithelial ovarian carcinoma (SEOC), we observed that allelic losses at D6S311 (6q23) and D6S149 (6q27) were significantly higher for PSCP than for SEOC. "
03/01/1998 - "Both mesotheliomas and PSCP arise from the coelomic epithelium, but are clinicopathologically and biologically distinct entities. "
03/01/1998 - "Although rare, PSCP is a diagnostically distinct entity the treatment of which is similar to ovarian serous tumors rather than mesotheliomas."
08/01/1995 - "Immunohistochemical studies using a panel of monoclonal antibodies against carbohydrates showed that Lewis Y is a good marker, in addition to S-100, placental alkaline phosphatase, CA125, and CD15 for separating PSCP from malignant mesothelioma (MM). "
|3.||Proteins (Proteins, Gene)
|4.||DNA (Deoxyribonucleic Acid)
|8.||Snake Venoms (Snake Venom)
|1.||Drug Therapy (Chemotherapy)
|4.||Combination Drug Therapy (Combination Chemotherapy)